83 results
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
17 Jun 24
Entry into a Material Definitive Agreement
9:04am
, to founding, leading and funding start-ups and early-stage biopharma companies. As a long-term investor in the healthcare sector, Dr. Glass is a founder … and principal of Medpro Investors, a New York-based venture capital firm focused on the healthcare sector. He is a long-term consultant and regulatory
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
6 Dec 23
Regulation FD Disclosure
9:15am
that causes chronic inflammation of the joints and affects approximately 1.5 million Americans. RA’s cost to society, including healthcare costs; loss
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
4 Oct 23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4:30pm
affect millions of patients, caregivers and their healthcare professionals, is what compels us to continue this important research.”
The Company
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
14 Aug 23
Regulation FD Disclosure
8:30am
, the burden to patients, care providers and society is striking, with an estimated annual cost of $39.2 billion.4 The price tag includes healthcare costs
8-K
EX-99.1
jig ts3og6y7buhncm
26 Oct 21
Regulation FD Disclosure
11:00am
8-K
EX-99.1
xazocnf
19 Oct 21
Regulation FD Disclosure
10:30am